The hypothesis for this study is that a preparative regimen that maximizes host
immunosuppression without myeloablation will be well tolerated and sufficient for
engraftment of donor hematopoietic cells. It is also to determine major toxicities from
these conditioning regimens, within the first 100 days after transplantation.
Additional locations may be listed on ClinicalTrials.gov for NCT00920972.
Locations matching your search criteria
United States
Connecticut
New Haven
Yale UniversityStatus: Active
Name Not Available
The study uses reduced intensity conditioning that is immune suppressive to achieve donor
cell engraftment without exposure to radiation or high dose chemotherapy in children with
non-malignant disorders. The intent is to minimize early and late regimen related
toxicities in the context of a reduced intensity regimen.
In addition to maximizing opportunity for donor cell engraftment, the trial seeks to
minimize toxicities associated with transplant such as graft versus host disease and
employs GVHD prophylaxis that seeks to decrease rates of acute and chronic GVHD in the
setting of matched and mismatched donor stem cell transplants from marrow and cord blood
sources.
Lead OrganizationWashington University School of Medicine
